76
Views
13
CrossRef citations to date
0
Altmetric
Review

Gene- and immunotherapy for hepatocellular carcinoma

, &
Pages 507-523 | Published online: 22 Apr 2005

Bibliography

  • MURRAY CJ, LOPEZ AD: Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet (1997) 349(9061):1269–1276.
  • EL-SERAG HB, MASON AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl. J. Med. (1999) 340(10):745–750.
  • •Important epidemiological study indicating the apparent increase in incidence of HCC in the West.
  • LO CM, NGAN H, TSO WK et al: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology (2002) 35(5):1164–1171.
  • LLO VET JM, REAL MI, MONTANA X et al.: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Barcelona Liver Cancer Group. Lancet (2002) 359(9319):1734–1739.
  • PALMER DH, HUSSAIN SA, JOHNSON PJ: Systemic therapies for hepatocellular carcinoma. Expert Opin. Investig. Drugs (2004) 13(12):1555–1568.
  • NO AUTHORS LISTED: Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. CLIP Group (Cancer of the Liver Italian Programme) Lancet (1998) 352(9121):17–20.
  • YUEN MF, POON RT, LAI CL et a/.: A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology. (2002) 36(3):687–691. Erratum in: Hepatology (2003) 37(2):489.
  • LOPEZ JA, HART DN: Current issues in dendritic cell cancer immunotherapy. Curr. Opin. MoL Ther. (2002) 4(1):54–63.
  • ROMANO G, PACILIO C, GIORDANO A: Gene transfer technology in therapy: current applications and future goals. Stem Cells (1999) 17:191–202.
  • DYER MR, HERRING PL: Progress and potential for gene-based medicine. Mo/. Ther. (2000) 1:213–224.
  • SOBOL RE, SHAWLER DL, CARSON C et al.: Interleukin 2 gene therapy of colorectal carcinoma with autologous irradiated tumor cells and genetically engineered fibroblasts: a Phase I study. Clin. Cancer Res. (1999) 5(9):2359–2365.
  • GEROLAMI R, UCH R, FAIVRE Jet al.:Herpes simplex virus thymidine kinase-mediated suicide gene therapy for hepatocellular carcinoma using HIV-1-derived lentiviral vectors. J. HepatoL (2004) 40(2):291–297.
  • HASEGAWA H, SHIMADA M, YONEMITSU Yet al.: Preclinical and therapeutic utility of HVJ liposomes as a gene transfer vector for hepatocellular carcinoma using herpes simplex virus thymidine kinase. Cancer Gene Ther. (2001) 8(4):252–258.
  • ANDERSON SC, JOHNSON DE, HARRIS MP et al.: p53 gene therapy in a rat model of hepatocellular carcinoma: intra-arterial delivery of a recombinant adenovirus. Clin. Cancer Res. (1998) 4(7):1649–1659.
  • XU GW, SUN ZT, FORRESTER K, WANG XW, COURSEN J, HARRIS CC: Tissue-specific growth suppression and chemosensitivity promotion in human hepatocellular carcinoma cells by retroviral-mediated transfer of the wild-type p53 gene. Hepatology (1996) 24(5):1264–1268.
  • BOUVET M, ELLIS LM, NISHIZAKI M et al.: Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res. (1998) 58(11):2288–2292.
  • HABIB NA, DING SF, EL-MASRY R et al.: Preliminary report: the short-term effects of direct p53 DNA injection in primary hepatocellular carcinomas. Cancer Detect. Prey. (1996) 20(2):103–107.
  • NGUYEN DM, SPITZ FR, YEN N, CRISTIANO RJ, ROTH JA: Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. J. Thorac. Cardiovasc. Surg (1996) 112(5):1372–1376; discussion 1376–1377.
  • ROTH JA, SWISHER SG, MEYN RE: p53 tumor suppressor gene therapy for cancer. Oncology (Huntingt.) (1999) 13(10 Suppl. 5):148–154.
  • KURIYAMA S, KIKUKAWA M, MASUI K et al.: Cytosine deaminase/ 5-fluorocytosine gene therapy can induce efficient anti-tumor effects and protective immunity in immunocompetent mice but not in athymic nude. Int. J. Cancer (1999) 81(4):592–597.
  • LINK CJ JR, LEVY JP, MCCANN LZ, MOORMAN DW: Gene therapy for colon cancer with the herpes simplex thymidine kinase gene. J. Surg Oncol. (1997) 64(4):289–294.
  • TRASK TW, TRASK RP, AGUILAR-CORDOVA E et aL: Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. MoL Ther. (2000) 1(2):195–203.
  • HERMAN JR, ADLER HL, AGUILAR-CORDOVA E et aL: In situ gene therapy for adenocarcinoma of the prostate: a Phase I clinical trial. Hum. Gene Ther. (1999) 10(7):1239–1249.
  • SUNG MW, YEH HC, THUNG SN et aL: Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: results of a Phase I clinical trial. MoL Ther. (2001) 4(3):182–191.
  • HUBER BE, AUSTIN EA, RICHARDS CA, DAVIS ST, GOOD SS: Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc. Natl. Acad. Sci. USA (1994) 91(17):8302–8306.
  • •Demonstration of the bystander effect associated with prodrug-activating gene therapy.
  • CHUNG-FAYE GA, CHEN MJ, GREEN NK et aL: In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase. Gene Ther. (2001) 8(20):1547–1554.
  • GREEN NK, YOUNGS DJ, NEOPTOLEMOS JP et aL: Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-y1)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. eat nitroreductase gene. Cancer Gene Ther. (1997) 4(4):229–238.
  • DJEHA AH, THOMSON TA, LEUNG H et al.: Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid tumors. MoL Ther. (2001) 3(2):233–240.
  • CHUNG-FAYE G, PALMER D, ANDERSON D et aL: Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a Phase I and pharmacokinetic study of its prodrug, CB1954. Clin. Cancer Res. (2001) 7(9):2662–2668.
  • PALMER DH, MAUTNER V, MIRZA D et aL: Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. J. Clin. OncoL (2004) 22(9):1546–1552.
  • •Demonstration of the extent of transgene expression in resected tumour specimens achieved via a replication-defective adenovirus vector.
  • CHANG TK, WEBER GF, CRESPI CL, WAXMAN DJ: Differential activation of cyclophosphamide and ifosphamide by cytochromes P450 2B and 3A in human liver microsomes. Cancer Res. (1993) 53(23):5629–5637.
  • MARAIS R, SPOONER RA, LIGHT Y, MARTIN J, SPRINGER CJ: Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination. Cancer Res. (1996) 56(20):4735–4742.
  • KOJIMA A, HACKETT NR, OHWADA A, CRYSTAL RG: In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors. J. Clin. Invest. (1998) 101(8):1789–1796.
  • ROGULSKI KR, KIM JH, KIM SH, FREYTAG SO: Glioma cells transduced with an Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Hum. Gene Ther. (1997) 8(1):73–85.
  • JU DW, WANG BM, GAO X: Adenovirus-mediated combined suicide gene and interleukin-2 gene therapy for the treatment of established tumor and induction of antitumor immunity. J. Cancer Res. Clin. OncoL (1998) 124(12):683–689.
  • SMITH ER, CHIOCCA EA: Oncolytic viruses as novel anticancer agents: turning one scourge against another. Expert Opin. Investig Drugs (2000) 9(2): 311–327.
  • WILDNER O, BLAESE RM, MORRIS JC: Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res. (1999) 59(2):410–413.
  • BISCHOFF JR, KIRN DH, WILLIAMS A et al.: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (1996) 274(5286):373–376.
  • ••Key paper reporting the development of conditionally replicating adenovirus.
  • RIES SJ, BRANDTS CH, CHUNG AS et al.: Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant d11520 (ONYX-015). Nat. Med. (2000) 6(10):1128–1133.
  • HONDA K, SBISA E, TULLO A et al.: p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation. Br. J. Cancer (1998) 77(5):776–782.
  • HABIB NA, MITRY RR, SARRAF CE et al.: Assessment of growth inhibition and morphological changes in in vitro and in vivo hepatocellular carcinoma models post treatment with d11520 adenovirus. Cancer Gene Ther. (2002) 9(5):414–420.
  • VOLLMER CM, RIBAS A. BUTTERFIELD LH et al.: p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma. Cancer Res. (1999) 59(17):4369–4374.
  • KIRN D: Oncolytic virotherapy for cancer with the adenovirus d11520 (Onyx-015): results of Phase I and II trials. Expert Opin. Biol. Ther. (2001) 1(3):525–538.
  • HABIB NA, SARRAF CE, MITRY RR et al.: El B-deleted adenovirus (dll 520) gene therapy for patients with primary and secondary liver tumors. Hum. Gene Ther. (2001) 12(3):219–226.
  • HABIB N, SALAMA H, ABD EL LATIF ABU MEDIAN A et aL: Clinical trial of El B-deleted adenovirus (d11520) gene therapy for hepatocellular carcinoma. Cancer Gene Ther. (2002) 9(3):254–259.
  • KHURI FR, NEMUNAITIS J, GANLY I et al.: A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. (2000) 6(8):879–885.
  • HEISE C, HERMISTON T, JOHNSON L et al.: An adenovirus ElA mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat. Med. (2000) 6(10):1134–1139.
  • EBERT O, SHINOZAKI K, HUANG TG, SAVONTAUS MJ, GARCIA-SASTRE A, WOO SL: Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats. Cancer Res. (2003) 63(13):3605–3611.
  • CARROLL NM, CHASE M, CHIOCCA EA, TANABE KK: The effect of ganciclovir on herpes simplex virus-mediated oncolysis. j Surg. Res. (1997) 69(2):413–417.
  • ROGULSKI KR, WING MS, PAIELLI DL, GILBERT JD, KIM JH, FREYTAG SO: Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization. Hum. Gene Ther. (2000) 11(1):67–76.
  • CHEN MJ, GREEN NK, REYNOLDS GM et al.: Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an El B-55K-deleted oncolytic adenovirus vector. Gene Ther. (2004) 11(14):1126–1136.
  • ANDREANSKY S, HE B, VAN COTT J et al.: Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther. (1998) 5(1):121–130.
  • ADVANI SJ, SIBLEY GS, SONG PY et al.:Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors. Gene Ther. (1998) 5(2):160–165.
  • SHIBA H, OKAMOTO T, FUTAGAWAY, OHASHI T, ETO Y: Efficient and cancer-selective gene transfer to hepatocellular carcinoma in a rat using adenovirus vector with iodized oil esters. Cancer Gene Ther. (2001) 8(10):713–718.
  • DOUGLAS JT, ROGERS BE, ROSENFELD ME et al.: Targeted gene delivery by tropism-modified adenoviral vectors. Nat. BiotechnoL (1996) 14:1574–1578.
  • WEITMAN SD, LARK RH, CONEY LR et aL: Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. (1992) 52:3396–3401.
  • FISHER KD, STALLWOOD Y, GREEN NK, ULBRICH K, MAUTNER V SEYMOUR LW: Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther. (2001) 8:341–348.
  • SEYMOUR LW, FERRY DR, ANDERSON D et aL: Hepatic drug targeting: Phase I evaluation of polymer-bound doxorubicin. j Clin. OncoL (2002) 20(6):1668–1676.
  • MOHR L, YEUNG A, ALOMAN C, WITTRUP D, WANDS JR: Antibody-directed therapy for human hepatocellular carcinoma. Gastroenterology (2004) 127(5 Suppl. 1):5225–5231.
  • WOLSCHEK MF, THALLINGER C, KURSA M et al.: Specific systemic nonviral gene delivery to human hepatocellular carcinoma xenografts in SCID mice. Hepatology (2002) 36(5):1106–1114.
  • MOHR L, SCHAUER JI, BOUTIN RH, MORADPOUR D, WANDS JR: Targeted gene transfer to hepatocellular carcinoma cells in vitro using a novel monoclonal antibody-based gene delivery system. Hepatology (1999) 29(1):82–89.
  • MILLER N, WHELAN J: Progress in transcriptionally targeted and regulatable vectors for genetic therapy. Hum. Gene Ther. (1997) 8(7):803–815.
  • CAMPER SA, TILGHMAN SM: The activation and silencing of gene transcription in the liver. Biotechnology (1991) 16:81–87.
  • YOON SS, NAKAMURA H, CARROLL NM, BODE BP, CHIOCCA EA, TANABE KK: An oncolytic herpes simplex virus Type 1 selectively destroys diffuse liver metastases from colon carcinoma. FASEB J. (2000) 14(2):301–311.
  • CAO G, KURIYAMA S, GAO Jet aL: Gene therapy for hepatocellular carcinoma based on tumour-selective suicide gene expression using the alpha-fetoprotein (AFP) enhancer and a housekeeping gene promoter. Eur. j Cancer (2001) 37(1):140–147.
  • WILLS KN, HUANG WM, HARRIS MP, MACHEMER T, MANEVAL DC, GREGORY RJ: Gene therapy for hepatocellular carcinoma: chemosensitivity conferred by adenovirus-mediated transfer of the HSV-1 thymidine kinase gene. Cancer Gene Ther. (1995) 2(3):191–197.
  • KANEKO S, HALLENBECK P, KOTANI T et al.: Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res. (1995) 55(22):5283–5287.
  • HUANG X, ZHANG W, WAKIMOTO H, HAIVIADA H, GAO X: Adenovirus-mediated tissue-specific cytosine deaminase gene therapy for human hepatocellular carcinoma with different AFP expression levels. J. Exp. Ther. Oncol (2002) 2(2):100–106.
  • GAO G, KURIYAMA S, TSUJINOUE H, CHEN Q, MITORO A. QI Z: A novel approach for inducing enhanced and selective transgene expression in hepatocellular-carcinoma cells. Int. J. Cancer (2000) 87(2):247–252.
  • IDO A, UTO H, MORIUCHI A et ell.: Gene therapy targeting for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by a hypoxia-inducible enhancer linked to a human alpha-fetoprotein promoter. Cancer Res. (2001) 61(7):3016–3021.
  • KUNITOMI M, TAKAYAMA E, SUZUKI S et al.: Selective inhibition of hepatoma cells using diphtheria toxin A under the control of the promoter/enhancer region of the human alpha-fetoprotein gene. Jpn. J. Cancer Res. (2000) 91(3):343–350.
  • HALLENBECK PL, CHANG YN, HAY C et al.: A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum. Gene Ther. (1999) 10(10):1721–1733.
  • TAKAHASHI M, SATO T, SAGAWA T et al.: E1B-55K-deleted adenovirus expressing E1A-135 by AFP enhancer/ promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor. Mo/. Ther. (2002) 5(5 Pt 0:627–634.
  • MIYATAKE SI, TANI S, FEIGENBAUM F et al.: Hepatoma-specific antitumor activity of an albumin enhancer/ promoter regulated herpes simplex virus in vivo. Gene Ther. (1999) 6(0564–572.
  • WANG XW, FORRESTER K, YEH H, FEITELSON Mk GU JR, HARRIS CC: Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Nail. Acad. Sci. USA (1994) 91(0:2230–2234.
  • HAVIV I, SHAMAY M, DOITSH G, SHAUL Y: Hepatitis B virus pX targets TFIIB in transcription coactivation. Mol Cell. Biol. (1998) 18(3):1562–1569.
  • MA C, SUN W, TIAN P et ell.: Effect of preS2 antisense RNA on hepatocellular carcinoma with a novel delivery system. Chin. Med. J. (Engl.) (2003) 116(5):717–720.
  • AOKI Y, CIOCA DP, OIDAIRA H, KAMIYA J, KIYOSAWA K: RNA interference may be more potent than antisense RNA in human cancer cell lines. Clin. Exp. Pharmacol Physiol (2003) 30(1-2):96–102.
  • CHEN Y, DUD, WI] Jet al.: Inhibition of hepatitis B virus replication by stably expressed shRNA. Biochem. Biophys. Res. Commun. (2003) 311(2):398–404.
  • SCHMITZ V WANG L, BARAJAS M, GOMAR C, PRIETO J, QIAN C: Treatment of colorectal and hepatocellular carcinomas by adenoviral mediated gene transfer of endostatin and angiostatin-like molecule in mice. Gut (2004) 53(4):561–567.
  • SCHWARTZ JD, SCHWARTZ M, GOLDMAN Jet al.: Bevacizumab in hepatocellular carcinoma in patients without metastasis and without invasion of the portal vein. J. Clin. Oncol (2004) ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22(14 Suppl.):4088.
  • STEWARD WP, THOMAS A, MORGAN B et al.: Expanded Phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with FOLFOX-4 as first-line treatment for patients with metastatic colorectal cancer. J. Clin. Oncol (2004) ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22(14 Suppl.):3556.
  • TRAN PL, VIGNERON JP, PERICAT D et al.: Gene therapy for hepatocellular carcinoma using non-viral vectors composed of bis guanidinium-tren-cholesterol and plasmids encoding the tissue inhibitors of metalloproteinases TIMP-2 and TIMP-3. Cancer Gene Ther. (2003) 10(6):435–444.
  • KORNBERG RD, LORCH Y: Chromatin-modifying and -remodeling complexes. Curr. Opin. Genet. Dev. (1999) 9(2):148–151.
  • GAETANO C, CATALANO A, PALUMBO R et al.: Transcriptionally active drugs improve adenovirus vector performance in vitro and in vivo. Gene Ther. (2000) 7(19):1624–1630.
  • WILDNER O, BLAESE RM, MORRIS JC: Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res. (1999) 59(2):410–413.
  • KHURI FR, NEMUNAITIS J, GANLY I et al.: A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. (2000) 6(8):879–885.
  • ROGULSKI KR, WING MS, PAIELLI DL, GILBERT JD, KIM JH, FREYTAG SO: Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization. Hum. Gene Ther. (2000) 11(1):67–76.
  • VILE RG, RUSSELL SJ, LEMOINE NR: Cancer gene therapy: hard lessons and new courses. Gene Ther. (2000) 7(1):2–8.
  • HARDY S, KITAMURA M, HARRIS-STANSIL T, DAI Y, PHIPPS ML: Construction of adenovirus vectors through Cre-lox recombination. (1997) 71(3):1842–1849.
  • REYNOLDS PN, FENG MZ, CURIEL DT: Chimeric viral vectors - the best of both worlds? MoL Med. Today (1999) 5:25–31.
  • ZHANG WW: Development and application of adenoviral vectors for gene therapy of cancer. Cancer Gene Ther. (1999) 6(2):113–138.
  • ALEMANY R, LAI S, LOU YC, JAN HY, FANG X, ZHANG WW: Complementary adenoviral vectors for oncolysis. Cancer Gene Ther. (1999) 6(1):21–25.
  • BARTLETT JS, SAMULSKI RJ: Fluorescent viral vectors: a new technique for the pharmacological analysis of gene therapy. Nat. Med. (1998) 4(5):635–637.
  • YOONG KF, AFFORD SC, JONES R et al.: Expression and function of CXC and CC chemokines in human malignant liver tumors: a role for human monokine induced by gamma-interferon in lymphocyte recruitment to hepatocellular carcinoma. Hepatology (1999) 30(1):100–111.
  • YOONG KF, ADAMS DH: Phenotypic and functional analyses of fresh and recombinant interleukin-2 cultured tumour-infiltrating lymphocytes derived from malignant human liver tumours. Biochem. Soc. Trans. (1997) 25(2):271S.
  • •Evidence of tumour-infiltrating lymphocytes in HCC, such that it may be a target for immunotherapy.
  • TODRYK SM, CHONG H, VILE RG, PANDHA H, LEMOINE NR: Can immunotherapy by gene transfer tip the balance against colorectal cancer? Gut (1998) 43(4):445–449.
  • BODEY B, BODEY B JR, SIEGEL SE, KAISER HE: Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Anticancer Res. (2000) 20(4):2665–2676.
  • FAKHRAI H, SHAWLER DL, GJERSET R et al.: Cytokine gene therapy with interleukin-2-transduced fibroblasts: effects of IL-2 dose on anti-tumor immunity. Hum. Gene Ther. (1995) 6(5):591–601.
  • SOBOL RE, SHAWLER DL, CARSON C et al.: Interleukin 2 gene therapy of colorectal carcinoma with autologous irradiated tumor cells and genetically engineered fibroblasts: a Phase I study. Clin. Cancer Res. (1999) 5(9):2359–2365.
  • SUMINAMI Y, ELDER EM, LOTZE MT, WHITESIDE TL: In situ interleukin-4 gene expression in cancer patients treated with genetically modified tumor vaccine. J. Immunother. Emphasis Tumor Immunol (1995) 17(4):238–248.
  • GEUTSKENS SB, VAN DER EB MM, PLOMP AC et al.: Recombinant adenoviral vectors have adjuvant activity and stimulate T cell responses against tumor cells. Gene Ther. (2000) 7(16):1410–1416.
  • BARAJAS M, MAZZOLINI G, GENOVE G et al.: Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12. Hepatology (2001) 33(1):52–61.
  • SANGRO B, MAZZOLINI G, RUIZ J et al.: Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J. Clin. Oncol (2004) 22(8):1389–1397.
  • •Clinical trial of cytokine immunogene therapy in HCC with clinical and biological end points.
  • PUTZER BM, HITT M, MULLER WJ, EMTAGE P, GAULDIE J, GRAHAM FL: Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression. Proc. Natl. Acad. Sci. USA (1997) 94:10889–10894.
  • NESTLE FO, ALIJAGIC S, GILLIET M et al.: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. (1998) 4(3):328–332.
  • SMALL EJ, FRATESI P, REESE DM et al.: Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol (2000) 18(23):3894–3903.
  • HOLTL L, RIESER C, PAPESH C et ell.: Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J. Urol. (1999) 161(3):777–782.
  • NINOMIYA T, AKBAR SM, MASUMOTO T, HORIIKE N, ONJI M: Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma. J. Hepatol. (1999) 31(2):323–331.
  • PALMER DH, MIDGLEY RS, MIRZA N et al.: A Phase I/II Study of adoptive immunotherapy in patients with hepatocellular carcinoma using dendritic cells pulsed with tumour lysate. British Association for Study of the Liver Annual Meeting. London, UK (2003).
  • IWASHITA Y, TAHARA K, GOTO S et al.: A Phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer. Cancer Immunol Immunother. (2003) 52(3):155–161.
  • BUTTERFIELD LH, RIBAS A, MENG WS et al.: T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. Clin. Cancer Res. (2003) 9(16 Pt 1):5902–5908.
  • LAI CL, LAU JY, WU PC et ell.: Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology (1993) 17(3):389–394.
  • LLOVET JM, SALA M, CASTELLS L et al.: Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology (2000) 31(1):54–58.
  • LAI CL, WU PC, LOK AS et ell.: Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial. Br. J. Cancer (1989) 60(6):928–933.
  • MABED M, EL-HELW L, SHAMAA S: Phase II study of viscum fraxini-2 in patients with advanced hepatocellular carcinoma. Br. J. Cancer (2004) 90(1):65–69.
  • HUSSAIN SA FERRY DR, EL-GAZZAZ G et al.: Hepatocellular carcinoma. Ann. Oncol (2001) 12(2):161–172.
  • WU CC, HO YZ, HO WL, WU TC, LIU TJ, P'ENG FK: Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal. Br. J. Surg. (1995) 82(1):122–126.
  • IZUMI R, SHIMIZU K, IYOBE T et al.: Postoperative adjuvant hepatic arterial infusion of Lipiodol containing anticancer drugs in patients with hepatocellular carcinoma. Hepatology (1994) 20(2):295–301.
  • ONO T, NAGASUE N, KOHNO H et al.: Adjuvant chemotherapy with epirubicin and carmofitr after radical resection of hepatocellular carcinoma: a prospective randomized study. Semin. Oncol (1997) 24(2 Suppl. 6):56-18-56-25.
  • KOHNO H, NAGASUE N, HAYASHI T et al.: Postoperative adjuvant chemotherapy after radical hepatic resection for hepatocellular carcinoma (HCC). Hepatogastroentero/ogy (1996) 43(12):1405–1409.
  • MUTO Y, MORIWAKI H, NINOMIYA M et al.: Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl. J. Med. (1996) 334(24):1561–1567.
  • LAU WY, LEUNG TW, HO SK et al.: Adjuvant intra-arterial iodine-131-labelled lipiodol for respectable hepatocellular carcinoma: a prospective randomised trial. Lancet (1999) 353(9155):797–801.
  • KUBO S, NISHIGUCHI S, HIROHASHI K et al.: Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann. Intern. Med. (2001) 134(10):963–967.
  • TAKAYAMA T, SEKINE T, MAKUUCHI M et al.: Adoptive immunotherapy to lower postsurgical 522 recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet (2000) 356(9232):802–807. Erratum in: Lancet (2000) 356(9242):1690.
  • •Evidence that immunotherapy may be beneficial in the adjuvant setting.
  • JONES RL, YOUNG LS, ADAMS DH: Immunotherapy in hepatocellular carcinoma. Lancet (2000) 356(9232):784–785.
  • RAMADORI G, FUZESI L, GRABBE E, PIELER T, ARMBRUST T: Successful treatment of hepatocellular carcinoma with the tyrosine kinase inhibitor imatinib in a patient with liver cirrhosis. Anticancer Drugs (2004) 15(4):405–409.
  • LUO G, HUANG S, XIE X et al.: Expression of cancer-testis genes in human hepatocellular carcinomas. Cancer Immun. (2002) 2:11. Website
  • http://www.iddb3.com/iddb3/iddb3_2/ reports.display?id=80646ctemplate=Drug6ci _query_id=3670645 IDdb drug search.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.